Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 39

1.

Decision analysis of tamoxifen for the prevention of invasive breast cancer.

Grann VR, Sundararajan V, Jacobson JS, Whang W, Heitjan DF, Antman KH, Neugut AI.

Cancer J. 2000 May-Jun;6(3):169-78.

PMID:
10882333
[PubMed - indexed for MEDLINE]
2.

Hormonal therapies for early breast cancer: systematic review and economic evaluation.

Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.

Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.

PMID:
17610808
[PubMed - indexed for MEDLINE]
Free Article
3.

Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.

Imai H, Kuroi K, Ohsumi S, Ono M, Shimozuma K.

Breast Cancer. 2007;14(1):81-7. Review.

PMID:
17245000
[PubMed - indexed for MEDLINE]
Free Article
4.

Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M.

Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. Review.

PMID:
16959170
[PubMed - indexed for MEDLINE]
Free Article
5.

Tamoxifen: a review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer.

Bryson HM, Plosker GL.

Pharmacoeconomics. 1993 Jul;4(1):40-66. Review.

PMID:
10146967
[PubMed - indexed for MEDLINE]
6.

The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.

PMID:
17999840
[PubMed - indexed for MEDLINE]
Free Article
7.

Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis.

Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A.

Lancet. 2001 Jul 28;358(9278):277-86. Review.

PMID:
11498214
[PubMed - indexed for MEDLINE]
8.

Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.

Dunn C, Keam SJ.

Pharmacoeconomics. 2006;24(5):495-517. Review.

PMID:
16706574
[PubMed - indexed for MEDLINE]
9.

Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.

Jahanzeb M.

Clin Ther. 2007 Aug;29(8):1535-47. Review.

PMID:
17919537
[PubMed - indexed for MEDLINE]
10.

A systematic overview of chemotherapy effects in breast cancer.

Bergh J, J├Ânsson PE, Glimelius B, Nygren P; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):253-81. Review.

PMID:
11441936
[PubMed - indexed for MEDLINE]
11.

Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.

Vogel VG.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4413s-4418s; discussion 4411s-4412s. Review.

PMID:
11916233
[PubMed - indexed for MEDLINE]
12.

From adjuvant therapy to breast cancer prevention: BCPT and STAR.

Dunn BK, Ford LG.

Breast J. 2001 May-Jun;7(3):144-57. Review.

PMID:
11469927
[PubMed - indexed for MEDLINE]
13.

A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.

Buxton M, Caine N, Chase D, Connelly D, Grace A, Jackson C, Parkes J, Sharples L.

Health Technol Assess. 2006 Aug;10(27):iii-iv, ix-xi, 1-164. Review.

PMID:
16904046
[PubMed - indexed for MEDLINE]
Free Article
14.

Should tamoxifen be used in breast cancer prevention?

Kramer R, Brown P.

Drug Saf. 2004;27(13):979-89. Review.

PMID:
15471505
[PubMed - indexed for MEDLINE]
15.

American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.

Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG 3rd, Burstein HJ, Eisen A, Lipkus I, Pfister DG; American Society of Clinical Oncology Breast Cancer Technology Assessment Working Group.

J Clin Oncol. 2002 Aug 1;20(15):3328-43. Review.

PMID:
12149307
[PubMed - indexed for MEDLINE]
Free Article
16.

Breast cancer prevention: a summary of the chemoprevention trial with tamoxifen.

Gould K, Gates ML, Miaskowski C.

Oncol Nurs Forum. 1994 Jun;21(5):835-40. Review. Erratum in: Oncol Nurs Forum 1995 May;22(4):615.

PMID:
7937245
[PubMed - indexed for MEDLINE]
17.

[Is breast cancer prevention by tamoxifen possible?].

Namer M, Serin D, Ferrero JM.

Bull Cancer. 1995 Jul;82 Suppl 3:155s-167s. Review. French.

PMID:
7492828
[PubMed - indexed for MEDLINE]
18.

Tamoxifen for the primary prevention of breast cancer: a review and critique of the concept and trial.

Bush TL, Helzlsouer KJ.

Epidemiol Rev. 1993;15(1):233-43. Review.

PMID:
8405207
[PubMed - indexed for MEDLINE]
19.

Chemoprevention of breast cancer.

Powles TJ, Davey J, McKinna A.

Acta Oncol. 1989;28(6):865-7. Review.

PMID:
2692649
[PubMed - indexed for MEDLINE]
20.

Epidemiology, prevention, and early detection of breast cancer.

Helzlsouer KJ.

Curr Opin Oncol. 1994 Nov;6(6):541-8. Review.

PMID:
7827162
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk